Akeso Inc. announced that data from a phase Ib/II clinical study evaluating the combination of cadonilimab and pulocimab (an anti-VEGFR-2 antibody) in patients with immunotherapy (IO)-resistant NSCLC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results